Biologic Agents
ApprovedBiologic
Biologic Agents is one of 71 biologic programs targeting Arthritis. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Arthritis
#DrugCompanyPhaseTrials
1Simponi
Johnson & JohnsonPhase 3
Aleve
Alnylam PharmaceuticalsPhase 3
Stelara
Johnson & JohnsonPhase 3
Bimzelx
UCBPhase 3
Ilaris
NovartisPhase 3
Remicade
OOrganon and Co
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Tanezumab
PfizerPhase 3
AIN457
NovartisPhase 3
SHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biologic Agents. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details